Haemonetics Corporation
$5.68B- Market cap
- $4.68B
- Debt
- +$1.24B
- Cash
- −$245.44M
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: HAE stock price at premium vs DOV $102.92 current versus $49.80 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DOV's multiple
Implied fair value · at HAE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · DOV FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 87% equity / 13% debt
DOV carries the larger enterprise value at $30.01B against $5.68B; DOV trades on the lower EV / Revenue multiple (3.71x vs 4.26x); DOV on the lower EV / EBITDA (16.19x vs 21.58x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
DOVER Corp · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.56x
0.54x
Net debt / EBITDA
Leverage against operating earnings
3.80x
—
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
—
Total debt
Interest-bearing obligations outstanding
$1.24B
$4.03B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BECTON DICKINSON & CO
HAE vs BDX
BAXTER INTERNATIONAL INC
HAE vs BAX
LivaNova PLC
HAE vs LIVN
STERIS plc
HAE vs STE
EMERSON ELECTRIC CO
HAE vs EMR
HONEYWELL INTERNATIONAL INC
HAE vs HON
DANAHER CORP /DE/
HAE vs DHR
Parker-Hannifin Corp
HAE vs PH
SPX Technologies, Inc.
HAE vs SPXC
IDEX CORP /DE/
HAE vs IEX
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.